Nanomedicines : design, delivery and detection [E-Book] / editor: Martin Braddock.
Braddock, Martin, (editor)
[Cambridge] : Royal Society of Chemistry, 2016
1 online resource.
RSC drug discovery ; 51
Full Text
Table of Contents:
  • Cover; Contents; Preface; Chapter 1 Design Considerations for Properties of Nanocarriers on Disposition and Efficiency of Drug and Gene Delivery; Chapter 2 Targeting Cyclins and Cyclin-dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy; Chapter 3 Nanoparticle Carriers to Overcome Biological Barriers to siRNA Delivery; Chapter 4 Magnetic Targeting as a Vehicle for the Delivery of Nanomedicines; Chapter 5 The Development of Theranostics
  • Imaging Considerations and Targeted Drug Delivery
  • Chapter 6 The Role of Imaging in Nanomedicine Development and Clinical TranslationChapter 7 Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedside; Chapter 8 Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101; Chapter 9 Nanodelivery Strategies in Breast Cancer Chemotherapy; Chapter 10 Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement; Chapter 11 Nanomedicine: Promises and Challenges; Chapter 12 The Challenge of Regulating Nanomedicine: Key Issues
  • Chapter 13 Doxil®
  • the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical UseSubject Index; References; 1.1 Introduction; 1.2 Types of Nanocarriers/Nanoparticles; 1.3 Physicochemical Factors that Affect Nanoparticle Efficiency; 1.4 Conclusions; References; 2.1 Introduction; 2.2 The Cell Cycle; 2.3 Deregulation of the Cell Cycle in Cancer; 2.4 RNA Interference; 2.5 Concluding Remarks; Acknowledgments; References; 3.1 Introduction; 3.2 Extracellular Barriers; 3.3 Cellular Barriers; 3.4 siRNA Delivery Systems; References; 4.1 Introduction
  • 4.2 External Magnetic Device4.3 Labeling Mesenchymal Stem Cells with Supraparamagnetic Iron Oxide; 4.4 Adhesion of m-MSCs to the Tissue Injured Site; 4.5 Animal Studies; 4.6 Conclusion; Acknowledgments; References; 5.1 Introduction; 5.2 Theranostic Carrier Materials; 5.3 Theranostics and Imaging; 5.4 Conclusions; References; 6.1 Introduction; 6.2 Imaging for In vivo Evaluation of the Spatio-temporal Distribution Characteristics of Nanomedicines; 6.3 Use of Imaging to Understand and Optimize Nanomedicine Performance; 6.4 Clinical Experience and Future Considerations; References
  • 7.1 Introduction7.2 Anticancer Agents Incorporating Micelles under Clinical Evaluation; 7.3 Verification of the EPR Effect using Imaging Mass Spectrometry; 7.4 Discussion and Conclusion; References; 8.1 Introduction; 8.2 Topoisomerase 1 Inhibitors; 8.3 Hypoxia Inducible Factor-1 Inhibitors; 8.4 Cancer Stem Cells; 8.5 Combination Therapy; 8.6 CRLX101; 8.7 Conclusion; References; 9.1 Introduction; 9.2 Nanocarriers for Drug Delivery to Solid Tumors; 9.3 Doxil®-The First FDA-approved Nano-drug; 9.4 Taxane-based Nanodelivery (Abraxane® and Genexol-PM®); 9.5 CrEL-free Formulations of PTX